Latest news with #IDE
Geeky Gadgets
6 days ago
- Business
- Geeky Gadgets
Trae AI: The Free AI Coding Tool That's Smarter Than Your IDE
What if your coding environment could think, adapt, and evolve alongside your projects—without costing you a dime? Enter Trae AI, a free alternative to traditional coding IDEs that's redefining the way developers approach their work. Unlike its well-known competitors like Visual Studio Code, Trae AI doesn't just stop at being functional; it's designed to be fantastic. With features like customizable coding agents and seamless integration of innovative AI models, this platform promises to streamline workflows, boost productivity, and empower developers to tackle even the most complex challenges. Whether you're debugging intricate code or experimenting with AI-driven applications, Trae AI offers a modern solution that's as versatile as it is powerful. In this breakdown, Prompt Engineering explore how Trae AI sets itself apart from the crowd. From its innovative Multi-Contextual Prompt Systems (MCPS) to its robust privacy measures, this IDE is packed with tools that cater to both the creative and technical needs of developers. You'll discover how Trae AI's AI model compatibility can push the boundaries of your projects and why its thoughtful design makes it accessible for developers of all skill levels. But is it truly the free, all-in-one solution it claims to be? Let's unpack its features, benefits, and potential limitations to see if Trae AI lives up to its bold promise of being the ultimate coding companion. Overview of Trae AI IDE TL;DR Key Takeaways : Trae AI is a free, modern IDE designed to rival platforms like Visual Studio Code, offering advanced customization, seamless AI integration, and robust privacy measures. Customizable coding agents with Multi-Contextual Prompt Systems (MCPS) streamline workflows, improve precision, and adapt to specific project needs. Supports integration with advanced AI models like Gemini 2.5 Pro, GPT-4.1, and Cloud 3.5 Sonnet, along with custom AI models via API keys for innovation and experimentation. Features include a clean user interface, real-time code execution previews, integrated web search, and tools for diverse projects like text-to-image generation and REST API integration. Emphasizes data privacy and security with local data storage, encrypted transmissions, and regional compliance options, making sure a secure development environment. Customizable Coding Agents for Enhanced Productivity A standout feature of Trae AI is its customizable coding agents, which are designed to streamline workflows and improve precision. These agents use Multi-Contextual Prompt Systems (MCPS) to handle complex, multi-layered instructions, allowing you to adapt tools and workflows to specific tasks. This level of customization ensures that your coding environment evolves alongside your projects, whether you're debugging intricate code, scripting automation processes, or developing APIs. By tailoring these agents to your unique requirements, you can significantly boost both productivity and accuracy, making Trae AI a powerful tool for developers seeking efficiency. Seamless AI Model Integration for Advanced Development Trae AI supports a wide range of advanced AI models, including Gemini 2.5 Pro, GPT-4.1, and Cloud 3.5 Sonnet. This compatibility allows you to select the model that best aligns with your project goals, making sure optimal performance and precision. Additionally, the platform offers the flexibility to integrate custom AI models via API keys, allowing experimentation and innovation. This feature is particularly beneficial for developers working on AI-driven applications, machine learning projects, or other innovative technologies. By providing seamless integration with these models, Trae AI enables you to push the boundaries of what is possible in software development. Free Cursor Alternative Trae AI Coding Assistant Gain further expertise in AI Coding IDE by checking out these recommendations. Features That Simplify and Enhance Your Workflow Trae AI is equipped with a robust set of features designed to simplify coding tasks and enhance overall productivity. Key highlights include: A clean and intuitive user interface that assists easy navigation and efficient project management. that assists easy navigation and efficient project management. Integrated web search capabilities , allowing you to access relevant information without leaving the IDE. , allowing you to access relevant information without leaving the IDE. Preconfigured MCPS options for quick access to documentation, examples, and templates . . Real-time code execution and output previews, allowing you to test and refine your code efficiently. These features work cohesively to create a seamless development experience, saving you time and effort while making sure high-quality results. Whether you're a beginner or an experienced developer, Trae AI's thoughtful design makes it accessible and practical for a wide range of users. Versatility Across Diverse Projects Trae AI's versatility makes it an ideal choice for a broad spectrum of applications. For example, the platform supports the development of text-to-image generators by integrating APIs such as Google's Gemini API. With built-in tools for image generation, regeneration, and downloading, Trae AI caters to both creative and technical projects. Additionally, its support for REST APIs simplifies the integration of external services, allowing you to expand the scope of your projects. Whether you're building innovative applications or managing routine tasks, Trae AI provides the tools and flexibility needed to bring your ideas to life. Privacy and Security: A Foundational Priority Trae AI places a strong emphasis on data privacy and security, making sure that your work remains protected at all times. The platform stores data locally and uses temporary uploads only for processing tasks, minimizing the risk of unauthorized access. All transmissions are encrypted, and strict access controls are implemented to safeguard your files. Furthermore, regional data deployment options allow you to comply with local regulations, making Trae AI a reliable choice for developers handling sensitive or confidential information. This commitment to security ensures peace of mind, allowing you to focus on your projects without concerns about data breaches or compliance issues. Optimized Usability for Developers of All Levels Designed with both simplicity and functionality in mind, Trae AI is particularly well-suited for small to medium-sized projects. Features such as code diffs and inline editing make it easy to track changes and refine your work, while the platform's extensive customization options allow you to tailor the environment to your specific needs. Although some AI models may have rate limits, Trae AI's comprehensive feature set ensures that it remains a strong alternative to traditional IDEs. Best of all, the platform is completely free, making it accessible to developers of all experience levels, from beginners to seasoned professionals. A Modern IDE Built for Today's Developers Trae AI stands out as a robust and secure coding IDE that prioritizes customization, functionality, and user experience. By integrating advanced AI models, customizable coding agents, and strong privacy measures, it offers a comprehensive solution for developers seeking a modern and efficient coding environment. Whether you're working on innovative AI applications, creative projects, or routine programming tasks, Trae AI equips you with the tools and flexibility to succeed. With its free access and versatile features, Trae AI is a valuable resource for developers looking to enhance their workflows and achieve their goals. Media Credit: Prompt Engineering Latest Geeky Gadgets Deals Some of our articles include affiliate links. If you buy something through one of these links, Geeky Gadgets may earn an affiliate commission. Learn about our Disclosure Policy
Yahoo
20-05-2025
- Business
- Yahoo
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - 75% systemic objective response rate (ORR) and 37.5% complete response rate meaningfully higher thus far than historical Keytruda® monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in head and neck squamous cell carcinoma (HNSCC) - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed locally advanced or metastatic pancreatic cancer -- MDSAP certification of the Company's Jerusalem facility meets the standards of the U.S., Australia, Brazil, Canada, and Japan, and completes audit for compliance with ISO 13485 - - FDA approval of IDE to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -- Completion of $36.9 million financing after balance sheet date bolsters the Company's capital position during ongoing acceleration of activities - JERUSALEM, May 19, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the 'Company') (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported first quarter 2025 financial results and provided a corporate update.'2025 has started off with a bang at Alpha Tau, with a flurry of important milestones as we continue to evaluate Alpha DaRT in treating internal organ tumors, expand our manufacturing capabilities, and prepare for commercial activities,' said Alpha Tau Chief Executive Officer Uzi Sofer. 'With four active U.S. IDEs approved by the FDA, and U.S. trials expected to begin soon in patients with newly-diagnosed pancreatic cancer and recurrent GBM, construction of the first phase of our Hudson, NH facility nearing completion, and our ambitions for the continued expansion of our clinical trial program, our recently completed financing came at the perfect time to ensure that our momentum continues to accelerate throughout the course of the year.' Recent Corporate Highlights: In April, Alpha Tau announced the completion of a $36.9 million registered direct financing from, and strategic marketing alliance with, an affiliate of Oramed Pharmaceuticals, Inc. (Oramed). Oramed CEO, President and Chairman Nadav Kidron has also joined the Alpha Tau Board of Directors, bringing years of public company biotech experience. In April, Alpha Tau announced receipt of an IDE from the FDA to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM). The clinical trial is expected to enroll up to ten U.S. patients with recurrent glioblastoma not amenable for surgical resection who have undergone a prior course of central nervous system radiation. In February, Alpha Tau announced achievement of Medical Device Single Audit Program (MDSAP) certification for the Company's manufacturing facility in Jerusalem. MDSAP was established by a coalition of international medical device regulatory authorities from Australia, Brazil, Canada, Japan and the U.S., to enable medical device manufacturers to be audited once for compliance with ISO 13485 and the standards of these five different markets. MDSAP certification may also speed the timetable to commercialization within these participating geographies, as it allows for a streamlined auditing process, providing manufacturers with a comprehensive approach to meet international regulatory standards efficiently. In January, Alpha Tau hosted a virtual R&D Update Day to present interim results from multiple trials as well as more information regarding the expected regulatory path forward in internal organs. Principal investigators presented data showing high disease control rate and strong interim safety results observed across three trials exploring the use of Alpha DaRT in pancreatic cancer patients, following a subset of the data presented by investigators at Hadassah Medical Center on a poster at the prestigious 2025 ASCO GI Symposium. Principal investigators also reported strong interim results in median survival of patients treated with Alpha DaRT after prior therapy as compared to previously published studies of alternative monotherapies, across all analyzed subgroups. At the R&D Update Day, positive interim results were also reported for the first eight patients recruited in a combination trial of Alpha DaRT with pembrolizumab (Keytruda), a checkpoint inhibitor, in treating patients with recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC). A reported systemic objective response rate of 75% and complete response rate of 37.5% were observed, compared to historical benchmarks of 19% and 5%, respectively, for pembrolizumab on its own in the KEYNOTE-048 trial. Approvals for two forthcoming clinical trials exploring the use of Alpha DaRT in treating pancreatic cancer were also announced during the R&D Update Day: IDE received from the FDA to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed pancreatic cancer, the first step toward regulatory approval in the U.S. The trial was initially approved for 12 patients with metastatic cancer and was then expanded to 30 patients in two cohorts of 15 patients each, one cohort of patients with newly diagnosed locally advanced cancer and the other of patients with newly diagnosed metastatic cancer. Approval from France's Ministry of Health to commence a French multicenter clinical trial of Alpha DaRT alongside capecitabine for patients with locally advanced pancreatic cancer, as well as a second study at a single center in France examining the use of Alpha DaRT delivered via Fine Needle System, or FNS, in the treatment of locally advanced pancreatic cancer. Expected Upcoming Milestone Targets: First patient enrolled in pancreatic cancer pilot study in the U.S. in Q3 2025. For more information, please see here: First patient treated in Israel for brain cancer in Q2 or Q3 2025. Completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in Q3 2025. For more information, please see here: First patient treated in U.S. GBM pilot study in H2 2025. For more information, please see here: Response from Japan's PMDA in H2 2025 to application for pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer. Financial results for quarter ended March 31, 2025 R&D expenses for the three months ended March 31, 2025 were $7.2 million, compared to $6.4 million for the same period in 2024, due to increased employee compensation and benefits, increased production expenses and reduced government grants, offset by lower share-based compensation expenses. Marketing expenses for the three months ended March 31, 2025 were $0.5 million, compared to $0.5 million for the same period in 2024. G&A expenses for the three months ended March 31, 2025 were $1.7 million, compared to $1.4 million for the same period in 2024, primarily due to increased employee compensation and benefits, including share-based compensation, and increased professional fees (including legal expenses).Financial income, net, for the three months ended March 31, 2025 was $0.7 million, compared to $0.4 million for the same period in 2024, due to a decrease in expense from remeasurement of warrants, offset by a decrease in interest from bank the three months ended March 31, 2025, the Company had a net loss of $8.7 million, or $0.12 per share, compared to a net loss of $8.0 million, or $0.11 per share, in the three months ending March 31, 2024. Balance Sheet Highlights As of March 31, 2025, the Company had cash and cash equivalents, short-term deposits and restricted deposits in the amount of $54.8 million, compared to $62.9 million at December 31, 2024. In April 2025, Alpha Tau raised $36.9 million through a registered direct financing transaction. About Alpha DaRT®Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv Statements This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 12, 2025, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release. Investor Relations Contact: IR@ BALANCE SHEET U.S. dollars in thousands December 31,2024 March 31,2025 Audited Unaudited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 13,724 $ 5,019 Short-term deposits 45,876 46,617 Restricted deposits 3,255 3,212 Prepaid expenses and other receivables 1,374 1,938 Total current assets 64,229 56,786 LONG-TERM ASSETS: Long term prepaid expenses 432 439 Property and equipment, net 13,934 16,191 Operating lease right-of-use assets 7,609 7,512 Total long-term assets 21,975 24,142 Total assets $ 86,204 $ 80,928 CONSOLIDATED BALANCE SHEET U.S. dollars in thousands December 31,2024 March 31, 2025 Audited Unaudited LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Trade Payables $ 3,531 $ 2,577 Other payables and accrued expenses 4,133 6,188 Current maturities of operating lease liabilities 1,011 1,001 Total current liabilities 8,675 9,766 LONG-TERM LIABILITIES: Long-term loan 5,561 5,472 Warrants liability 3,338 3,545 Operating lease liabilities 5,964 5,820 Total long-term liabilities 14,863 14,837 Total liabilities 23,538 24,603 SHAREHOLDERS' EQUITY: Share capital Ordinary shares of no-par value per share – Authorized: 362,116,800 shares as of December 31, 2024 and March 31, 2025; Issued and outstanding: 70,380,570 and 70,511,475 shares as of December 31, 2024 and March 31, 2025, respectively - - Additional paid-in capital 210,175 212,525 Accumulated deficit (147,509 ) (156,200 ) Total shareholders' equity 62,666 56,325 Total liabilities and shareholders' equity $ 86,204 $ 80,928 CONSOLIDATED STATEMENT OF OPERATIONS U.S. dollars in thousands (except share and per share data) Three months ended March 31, 2024 2025 Unaudited Research and development, net $ 6,448 $ 7,170 Marketing expenses 533 459 General and administrative expenses 1,443 1,679 Total operating loss 8,424 9,308 Financial income, net (444 ) (716 ) Loss before taxes on income 7,980 8,592 Tax on income 1 99 Net loss 7,981 8,691 Net comprehensive loss 7,981 8,691 Net loss per share, basic and diluted $ (0.11 ) $ (0.12 ) Weighted-average shares used in computing net loss per share, basic and diluted 69,714,250 70,450,897 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - 75% systemic objective response rate (ORR) and 37.5% complete response rate meaningfully higher thus far than historical Keytruda® monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in head and neck squamous cell carcinoma (HNSCC) - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed locally advanced or metastatic pancreatic cancer -- MDSAP certification of the Company's Jerusalem facility meets the standards of the U.S., Australia, Brazil, Canada, and Japan, and completes audit for compliance with ISO 13485 - - FDA approval of IDE to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -- Completion of $36.9 million financing after balance sheet date bolsters the Company's capital position during ongoing acceleration of activities - JERUSALEM, May 19, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the 'Company') (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported first quarter 2025 financial results and provided a corporate update.'2025 has started off with a bang at Alpha Tau, with a flurry of important milestones as we continue to evaluate Alpha DaRT in treating internal organ tumors, expand our manufacturing capabilities, and prepare for commercial activities,' said Alpha Tau Chief Executive Officer Uzi Sofer. 'With four active U.S. IDEs approved by the FDA, and U.S. trials expected to begin soon in patients with newly-diagnosed pancreatic cancer and recurrent GBM, construction of the first phase of our Hudson, NH facility nearing completion, and our ambitions for the continued expansion of our clinical trial program, our recently completed financing came at the perfect time to ensure that our momentum continues to accelerate throughout the course of the year.' Recent Corporate Highlights: In April, Alpha Tau announced the completion of a $36.9 million registered direct financing from, and strategic marketing alliance with, an affiliate of Oramed Pharmaceuticals, Inc. (Oramed). Oramed CEO, President and Chairman Nadav Kidron has also joined the Alpha Tau Board of Directors, bringing years of public company biotech experience. In April, Alpha Tau announced receipt of an IDE from the FDA to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM). The clinical trial is expected to enroll up to ten U.S. patients with recurrent glioblastoma not amenable for surgical resection who have undergone a prior course of central nervous system radiation. In February, Alpha Tau announced achievement of Medical Device Single Audit Program (MDSAP) certification for the Company's manufacturing facility in Jerusalem. MDSAP was established by a coalition of international medical device regulatory authorities from Australia, Brazil, Canada, Japan and the U.S., to enable medical device manufacturers to be audited once for compliance with ISO 13485 and the standards of these five different markets. MDSAP certification may also speed the timetable to commercialization within these participating geographies, as it allows for a streamlined auditing process, providing manufacturers with a comprehensive approach to meet international regulatory standards efficiently. In January, Alpha Tau hosted a virtual R&D Update Day to present interim results from multiple trials as well as more information regarding the expected regulatory path forward in internal organs. Principal investigators presented data showing high disease control rate and strong interim safety results observed across three trials exploring the use of Alpha DaRT in pancreatic cancer patients, following a subset of the data presented by investigators at Hadassah Medical Center on a poster at the prestigious 2025 ASCO GI Symposium. Principal investigators also reported strong interim results in median survival of patients treated with Alpha DaRT after prior therapy as compared to previously published studies of alternative monotherapies, across all analyzed subgroups. At the R&D Update Day, positive interim results were also reported for the first eight patients recruited in a combination trial of Alpha DaRT with pembrolizumab (Keytruda), a checkpoint inhibitor, in treating patients with recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC). A reported systemic objective response rate of 75% and complete response rate of 37.5% were observed, compared to historical benchmarks of 19% and 5%, respectively, for pembrolizumab on its own in the KEYNOTE-048 trial. Approvals for two forthcoming clinical trials exploring the use of Alpha DaRT in treating pancreatic cancer were also announced during the R&D Update Day: IDE received from the FDA to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed pancreatic cancer, the first step toward regulatory approval in the U.S. The trial was initially approved for 12 patients with metastatic cancer and was then expanded to 30 patients in two cohorts of 15 patients each, one cohort of patients with newly diagnosed locally advanced cancer and the other of patients with newly diagnosed metastatic cancer. Approval from France's Ministry of Health to commence a French multicenter clinical trial of Alpha DaRT alongside capecitabine for patients with locally advanced pancreatic cancer, as well as a second study at a single center in France examining the use of Alpha DaRT delivered via Fine Needle System, or FNS, in the treatment of locally advanced pancreatic cancer. Expected Upcoming Milestone Targets: First patient enrolled in pancreatic cancer pilot study in the U.S. in Q3 2025. For more information, please see here: First patient treated in Israel for brain cancer in Q2 or Q3 2025. Completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in Q3 2025. For more information, please see here: First patient treated in U.S. GBM pilot study in H2 2025. For more information, please see here: Response from Japan's PMDA in H2 2025 to application for pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer. Financial results for quarter ended March 31, 2025 R&D expenses for the three months ended March 31, 2025 were $7.2 million, compared to $6.4 million for the same period in 2024, due to increased employee compensation and benefits, increased production expenses and reduced government grants, offset by lower share-based compensation expenses. Marketing expenses for the three months ended March 31, 2025 were $0.5 million, compared to $0.5 million for the same period in 2024. G&A expenses for the three months ended March 31, 2025 were $1.7 million, compared to $1.4 million for the same period in 2024, primarily due to increased employee compensation and benefits, including share-based compensation, and increased professional fees (including legal expenses).Financial income, net, for the three months ended March 31, 2025 was $0.7 million, compared to $0.4 million for the same period in 2024, due to a decrease in expense from remeasurement of warrants, offset by a decrease in interest from bank the three months ended March 31, 2025, the Company had a net loss of $8.7 million, or $0.12 per share, compared to a net loss of $8.0 million, or $0.11 per share, in the three months ending March 31, 2024. Balance Sheet Highlights As of March 31, 2025, the Company had cash and cash equivalents, short-term deposits and restricted deposits in the amount of $54.8 million, compared to $62.9 million at December 31, 2024. In April 2025, Alpha Tau raised $36.9 million through a registered direct financing transaction. About Alpha DaRT®Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv Statements This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 12, 2025, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release. Investor Relations Contact: IR@ BALANCE SHEET U.S. dollars in thousands December 31,2024 March 31,2025 Audited Unaudited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 13,724 $ 5,019 Short-term deposits 45,876 46,617 Restricted deposits 3,255 3,212 Prepaid expenses and other receivables 1,374 1,938 Total current assets 64,229 56,786 LONG-TERM ASSETS: Long term prepaid expenses 432 439 Property and equipment, net 13,934 16,191 Operating lease right-of-use assets 7,609 7,512 Total long-term assets 21,975 24,142 Total assets $ 86,204 $ 80,928 CONSOLIDATED BALANCE SHEET U.S. dollars in thousands December 31,2024 March 31, 2025 Audited Unaudited LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Trade Payables $ 3,531 $ 2,577 Other payables and accrued expenses 4,133 6,188 Current maturities of operating lease liabilities 1,011 1,001 Total current liabilities 8,675 9,766 LONG-TERM LIABILITIES: Long-term loan 5,561 5,472 Warrants liability 3,338 3,545 Operating lease liabilities 5,964 5,820 Total long-term liabilities 14,863 14,837 Total liabilities 23,538 24,603 SHAREHOLDERS' EQUITY: Share capital Ordinary shares of no-par value per share – Authorized: 362,116,800 shares as of December 31, 2024 and March 31, 2025; Issued and outstanding: 70,380,570 and 70,511,475 shares as of December 31, 2024 and March 31, 2025, respectively - - Additional paid-in capital 210,175 212,525 Accumulated deficit (147,509 ) (156,200 ) Total shareholders' equity 62,666 56,325 Total liabilities and shareholders' equity $ 86,204 $ 80,928 CONSOLIDATED STATEMENT OF OPERATIONS U.S. dollars in thousands (except share and per share data) Three months ended March 31, 2024 2025 Unaudited Research and development, net $ 6,448 $ 7,170 Marketing expenses 533 459 General and administrative expenses 1,443 1,679 Total operating loss 8,424 9,308 Financial income, net (444 ) (716 ) Loss before taxes on income 7,980 8,592 Tax on income 1 99 Net loss 7,981 8,691 Net comprehensive loss 7,981 8,691 Net loss per share, basic and diluted $ (0.11 ) $ (0.12 ) Weighted-average shares used in computing net loss per share, basic and diluted 69,714,250 70,450,897
Technical.ly
16-05-2025
- Business
- Technical.ly
Biotech startup BioLattice wins pitch prize — but says the real value was showing up
Despite the international representation at BioLabs Philadelphia's third annual Investor Day, a local biotech company took home the top prize. Amelia Zellander, founder and CEO of tissue engineering startup BioLattice, applied for Investor Day as a way to attract funding and resources for her company, with the goal of making connections that could lead to valuable relationships, she said. The event featured 18 startups, all of which pitched to win Startup of the Year and a package of consulting services, software services and discounts on equipment. The startups were also exposed to life sciences stakeholders from across the country and those from outside the region got to meet Philly's ecosystem. Winning Startup of the Year means a lot, Zellander said, and helps to spread the word about the work she is doing. 'People invest in people they know and they like,' she told 'You just have to have face-to-face interaction, and nothing magical is going to happen for me at this one event. It's about being out there a lot.' Recognition from winning the award will help Zellander with her current goal, raising a $2 million seed round. The seed round will help the company file for an Investigational Device Exemption (IDE) from the Food and Drug Administration to generate data to show that the company is ready for a clinical trial, Zellander said. BioLattice is developing a biomaterial to repair and transplant the front layer of the eye called CorneaClear. The company has seen some momentum over the last few years, receiving funding from federal agencies, accelerators and pitch competitions that have supported the development of its prototype. It has some early data from animal tests to inform its pilot studies, but still needs more cash to get there. A slow funding environment isn't scaring BioLattice away Despite Zellander's recent wins, her experience with finding funding and resources for her company has always been a challenge. It's generally harder for life sciences companies to find funding because they're high risk and require long timelines. Lack of funding is exacerbated by funding cuts to the National Institutes of Health. The Philadelphia region saw a dip in venture capital last quarter and Philly companies say they are having trouble securing funding from local investors. Events like BioLabs Investor Day are intended to bring investors and money from outside Philadelphia into the region, Melina Blees, head of BioLabs Philadelphia, told But investors generally are looking for companies with strong teams that are capital efficient, have an exit timeline and proven customers. Plus, federal funding cuts are making it increasingly difficult for startups to get off the ground. However, these circumstances don't particularly scare Zellander, she said. Raising money and finding resources have always been difficult. In the past, she struggled to find consistent funding and balance her time building the startup while working full-time jobs, she said. 'It has just never been easy, and in my experience, it's always hard for just different reasons,' she said. Bringing outsiders to Philly to boost local VC BioLabs hosts events like this not just to engage with local stakeholders, but also to show off the region to investors who may write Philly off, Blees of BioLabs said. 'Our goal is really to bring them here, to show them that there's great science happening,' Blees said. 'Then hopefully that means they come back and they invest.' Biolabs' national presence is helpful for this, she said. The global life sciences coworking company hosts an investor event series in its hubs across the country, which works to build a network that can be tapped into by anyone. BioLabs launched in Philly in 2018 and is now doubling down on its presence here. The company recently announced plans to expand its space at the Curtis building. The BioLabs for Advanced Therapeutics will be a 30,000-square-foot incubator space to be completed in the second half of this year. The expansion includes the opening of the Thermo Fisher Scientific Advanced Therapies Collaboration Center, which is expected to bring in companies from all over to try equipment and work with the life science company's team, Blees said. Convincing investors that startups can be successful anywhere is easier since the pandemic introduced virtual work, she said. In fact, startups can be more successful in an ecosystem where they have connections and resources with a lower cost of living. 'Money can move,' Blees said. 'If a great company is embedded in an ecosystem and has the support and has resources, why would you move them?' Sarah Huffman is a 2022-2024 corps member for Report for America, an initiative of The Groundtruth Project that pairs young journalists with local newsrooms. This position is supported by the Lenfest Institute for Journalism.
AFP
06-05-2025
- Business
- AFP
CorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of Directors
CorFlow Therapeutics AG (CorFlow) is pleased to announce the appointment of Chris O'Connell as Chairman of the Board of Directors, replacing Rick Geoffrion who remains as a Director on the Board. Chris is a highly regarded senior executive, board member and advisor across the medical devices, life sciences and global healthcare industries. Chris built his career over 21 years at Medtronic (MDT) serving in multiple business areas and functions during an era of rapid expansion. This included senior leadership roles in the Cardiovascular and Diabetes business units, before becoming Executive Vice President and President of the Restorative Therapies Group. Chris was a member of the Medtronic Executive Committee for nine years. Chris later became CEO and President of the Waters Corporation (WAT) which he led to robust business and share price growth for over five years. He currently serves as an Independent Director of innovative growth companies in medical devices, life sciences and diagnostics, as well as several non-profit organizations. This press release features multimedia. View the full release here: Chris O'Connell, Chairman, Board of Directors, CorFlow Paul Mead, CEO of CorFlow, said 'Chris brings exceptional strategic and operational acumen to CorFlow at a pivotal growth phase, where the company can benefit tremendously from his experience. Chris knows exactly how high the bar is set for excellence across all functions in MedTech, both from his corporate and board experiences, and from having been on the buy side of many M&A transactions. On behalf of our board, shareholders, and employees, we're thrilled to have him on board.' Paul added, 'I would like to take this opportunity to extend my sincere gratitude for the personal support and commitment from Rick Geoffrion over the past few years, who I am glad will remain on our Board in an independent capacity.' Chris joins CorFlow as the company embarks on achieving ambitious Series B objectives, which include two parallel clinical trials, an FDA IDE trial to obtain marketing authorization in the United States, and a landmark randomized therapy trial in Europe. CorFlow's technology aims to be the first to both diagnose and deliver therapy for heart attack patients suffering from microvascular obstruction, with a precise system that fits into the existing workflow for interventional cardiologists. The company's first in human MOCA I study results have been presented at the recent TCT and EuroPCR scientific congresses, and preclinical findings at the European Society of Cardiology meeting. CorFlow closed a €44M Series B in late 2024 with an international venture capital syndicate, and recently added further capital for expanded clinical, R&D, and capability advancement. Chris commented, 'I am honored to join the CorFlow team, and highly motivated by the opportunity to help address a major unmet medical need for patients suffering from microvascular obstruction. CorFlow is poised for breakthrough success with such a transformative technology set, talented CEO and team, and experienced investor group. We have all the ingredients to achieve something special.' About CorFlow Therapeutics: Headquartered in Baar, Switzerland. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart. View source version on Media and Scientific Contact CorFlow Therapeutics AG hello@ © Business Wire, Inc. Avertissement : Ce communiqué de presse n'est pas un document produit par l'AFP. L'AFP décline toute responsabilité quant à son contenu. Pour toute question le concernant, veuillez contacter les personnes/entités indiquées dans le corps du communiqué de presse.
